Medical cannabis expert, Steve Goldner, CEO, interviewed live at the NYSE on the Cheddar Biz news channel to talk about support from the Food & Drug Administration through clinical trials. The medical cannabis experts at Pure Green Pharmaceuticals found  the FDA receptive to Pure Green’s medical CBDs efforts and the FDA proposed innovative regulatory approval pathways to reduce the opioid crisis. 

In developing medical CBD, Pure Green Pharmaceuticals has applied for eight patents and the very first was approved while the others are still under review for advancing the science and medicine behind CBD. Steve Goldner, CEO for Pure Green Pharmaceuticals, has invented a number of other drugs throughout his experience working with the FDA for the last 45 years. The tremendous regulatory expertise of the Pure Green medical CBD drug development team probably motivated  the FDA to provide a clear pathway to the market, approaching medical CBD as a solution for pain relief in osteoarthritis and diabetic neuropathy. In addition to these two pathways, additional trials have been conducted to reduce pain, aid in sleep, and reduce anxiety. The Pure Green Pharmaceuticals group is further hoping to offer clinical trials in medical CBD for menstrual pain. Utilizing FDA suggested pathways, the FDA and Pure Green Pharmaceuticals are hoping to solve patients pain with medical CBD before they turn to opioids.   

Through clinical trials on medical CBD conducted by Pure Green Pharmaceuticals, it has been confirmed that CBD in some concentrations can relieve pain, while being used in a safe and effective way. 

Through the clear pathway to market, Pure Green Pharmaceuticals is hopeful their upcoming Private Placement Memorandum will draw in investors to fund the clinical trial program. Because of Goldner’s industry experience and the successful clinical trials, the medical CBD developed by Pure Green Pharmaceuticals could reduce the opioid crisis by allowing people to use safer and more effective CBD.